Department of Immunotechnology, Lund University, 223 81 Lund, Sweden.
CREATE Health Cancer Center, Lund University, 223 81 Lund, Sweden.
Cells. 2024 May 28;13(11):926. doi: 10.3390/cells13110926.
Bladder cancer is a heterogenous disease, and molecular subtyping is a promising method to capture this variability. Currently, the immune compartment in relation to subtypes is poorly characterized. Here, we analyzed the immune compartment in bladder tumors and normal bladder urothelium with a focus on T cell subpopulations using flow cytometry and RNA sequencing. The results were investigated in relation to tumor invasiveness (NMIBC/MIBC) and molecular subtypes according to the Lund Taxonomy system. Whereas the NMIBC/MIBC differed in the overall immune infiltration only, the molecular subtypes differed both in terms of immune infiltration and immune compartment compositions. The Basal/Squamous (Ba/Sq) and genomically unstable (GU) tumors displayed increased immune infiltration compared to urothelial-like (Uro) tumors. Additionally, the GU tumors had a higher proportion of regulatory T cells within the immune compartment compared to Uro tumors. Furthermore, sequencing showed higher levels of exhaustion in CD8 T cells from GU tumors compared to both Uro tumors and the control. Although no such difference was detected at the transcriptomic level in Uro tumors compared to the controls, CD8 T cells in Uro tumors showed higher expression of several exhaustion markers at the protein level. Taken together, our findings indicate that depending on the molecular subtype, different immunotherapeutic interventions might be warranted.
膀胱癌是一种异质性疾病,分子亚型分析是捕捉这种变异性的一种很有前途的方法。目前,与亚型相关的免疫区室的特征描述很差。在这里,我们使用流式细胞术和 RNA 测序分析了膀胱癌和正常膀胱尿路上皮中的免疫区室,重点是 T 细胞亚群。根据 Lund 分类系统,将结果与肿瘤侵袭性(NMIBC/MIBC)和分子亚型进行了调查。尽管 NMIBC/MIBC 仅在整体免疫浸润方面存在差异,但分子亚型在免疫浸润和免疫区室组成方面均存在差异。基底/鳞状(Ba/Sq)和基因组不稳定(GU)肿瘤与尿路上皮样(Uro)肿瘤相比,免疫浸润增加。此外,与 Uro 肿瘤相比,GU 肿瘤的免疫区室中调节性 T 细胞的比例更高。此外,测序显示,与 Uro 肿瘤和对照相比,GU 肿瘤的 CD8 T 细胞中的耗竭水平更高。尽管在 Uro 肿瘤与对照相比,在转录组水平上未检测到这种差异,但 Uro 肿瘤中的 CD8 T 细胞在蛋白质水平上显示出几种耗竭标志物的表达更高。总之,我们的研究结果表明,根据分子亚型的不同,可能需要不同的免疫治疗干预措施。